This provides a novel mechanism for the benefit of PPX treatment in PD because accumulative evidence from the patient with PD and animal models shows that NLRP3 inflammasome activation contributes to the pathogenesis of PD. This evidence concerns the gene NLRP3 and Parkinson disease.